Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Needham Maintains Buy on Cormedix, Lowers Price Target to $12

CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position

CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position

CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4

CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop

Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases

CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027

A weekly antifungal is under priority review to prevent fungal disease during stem-cell transplants

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Actinium Pharmaceuticals Appoints Dr. Matt David As CFO

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference